The same pharmacogenomics that sits on our condition pages, read from the other end. People rarely arrive asking about SLCO1B1 — they arrive having been prescribed a statin. Each page below collects what published guidelines say about one drug, names the genes involved, and links to the variants your own file would contain.
Supplements — kept apart, with the evidence stated on each →
None of this is dosing guidance. Where a clinical guideline exists it is written for prescribers, and the pages say so. Nothing here is a reason to start, stop or change a medication.
A prodrug: it does nothing until an enzyme switches it on. People whose enzyme works poorly get less of the drug they were prescribed, and this is one of the few places where a guideline says to use a different medicine.
CYP2C19
See what the research says → AntiplateletA newer alternative to clopidogrel for acute coronary syndromes, taken directly rather than needing an enzyme to switch it on. Genetics moves its blood levels a measurable amount — and, unlike clopidogrel, that movement has not been shown to change how well it works.
SLCO1B1 · CYP3A4/CYP3A5 region
See what the research says →The same pharmacogenomics already published on our condition pages, read from the drug side instead: what published guidelines say about one medicine, which genes are involved, and the variants your own file would contain.
No. Where a clinical guideline exists it is written for prescribers, and nothing here is a reason to start, stop or change a medication — that belongs with the clinician or pharmacist managing treatment.
Because almost nothing sold as a supplement has a prescribing guideline behind it the way a drug does, and listing the two together would lend the second the authority of the first.
By gene symbol as a whole word, gathered from the pgx_notes already published on the condition pages that discuss each drug — not a second, separate copy of that information.